GH Research reports Q1 2026 results and progress toward GH001 Phase 3

GH Research PLC (GHRS) — GH Research reported a first-quarter 2026 loss of about $0.31 per share and cash, equivalents and marketable securities of $267.3 million as of March 31.

The company said it completed enrollment in its GH001-HV-106 clinical pharmacology trial and selected doses for its planned global Phase 3 pivotal program of inhaled mebufotenin (GH001) in treatment-resistant depression. GH Research said it is seeking FDA alignment while continuing to target Phase 3 initiation.

Source: investor.ghres.com

For the rest of that week's sector news, read our week in review.